Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, February 14, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Patrick Trucchio Maintained (VIR) at Strong Buy with Increased Target to $110 on, Feb 14th, 2024
Patrick Trucchio of HC Wainwright & Co., Maintained "Vir Biotechnology, Inc." (VIR) at Strong Buy with Increased Target from $85 to $110 on, Feb 14th, 2024.
Patrick has made no other calls on VIR in the last 4 months.
There are 2 other peers that have a rating on VIR. Out of the 2 peers that are also analyzing VIR, 1 agrees with Patrick's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Eric Joseph of "JP Morgan" Downgraded from Buy to Hold and Decreased Target to $9 on, Monday, January 29th, 2024
This is the rating of the analyst that currently disagrees with Patrick
- Joseph Stringer of "Needham" Maintained at Strong Buy with Decreased Target to $15 on, Friday, November 3rd, 2023
